These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 28670693)

  • 1. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma.
    Waldschmidt JM; Simon A; Wider D; Müller SJ; Follo M; Ihorst G; Decker S; Lorenz J; Chatterjee M; Azab AK; Duyster J; Wäsch R; Engelhardt M
    Br J Haematol; 2017 Oct; 179(1):36-49. PubMed ID: 28670693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma.
    Ren Z; Lantermans H; Kuil A; Kraan W; Arenzana-Seisdedos F; Kersten MJ; Spaargaren M; Pals ST
    J Hematol Oncol; 2021 Jan; 14(1):11. PubMed ID: 33436043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment.
    Li W; Ding Q; Ding Y; Lu L; Wang X; Zhang Y; Zhang X; Guo Q; Zhao L
    Mol Carcinog; 2017 Mar; 56(3):863-876. PubMed ID: 27533597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.
    Noborio-Hatano K; Kikuchi J; Takatoku M; Shimizu R; Wada T; Ueda M; Nobuyoshi M; Oh I; Sato K; Suzuki T; Ozaki K; Mori M; Nagai T; Muroi K; Kano Y; Furukawa Y; Ozawa K
    Oncogene; 2009 Jan; 28(2):231-42. PubMed ID: 18850009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrin β7-mediated regulation of multiple myeloma cell adhesion, migration, and invasion.
    Neri P; Ren L; Azab AK; Brentnall M; Gratton K; Klimowicz AC; Lin C; Duggan P; Tassone P; Mansoor A; Stewart DA; Boise LH; Ghobrial IM; Bahlis NJ
    Blood; 2011 Jun; 117(23):6202-13. PubMed ID: 21474670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
    Azab AK; Runnels JM; Pitsillides C; Moreau AS; Azab F; Leleu X; Jia X; Wright R; Ospina B; Carlson AL; Alt C; Burwick N; Roccaro AM; Ngo HT; Farag M; Melhem MR; Sacco A; Munshi NC; Hideshima T; Rollins BJ; Anderson KC; Kung AL; Lin CP; Ghobrial IM
    Blood; 2009 Apr; 113(18):4341-51. PubMed ID: 19139079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization.
    Hoellenriegel J; Zboralski D; Maasch C; Rosin NY; Wierda WG; Keating MJ; Kruschinski A; Burger JA
    Blood; 2014 Feb; 123(7):1032-9. PubMed ID: 24277076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of SDF-1/CXCR4 reduces adhesion-mediated chemoresistance of multiple myeloma cells via interacting with interleukin-6.
    Liu Y; Liang HM; Lv YQ; Tang SM; Cheng P
    J Cell Physiol; 2019 Nov; 234(11):19702-19714. PubMed ID: 30953364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The peptidomimetic CXCR4 antagonist TC14012 recruits beta-arrestin to CXCR7: roles of receptor domains.
    Gravel S; Malouf C; Boulais PE; Berchiche YA; Oishi S; Fujii N; Leduc R; Sinnett D; Heveker N
    J Biol Chem; 2010 Dec; 285(49):37939-43. PubMed ID: 20956518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.
    Yanamandra N; Colaco NM; Parquet NA; Buzzeo RW; Boulware D; Wright G; Perez LE; Dalton WS; Beaupre DM
    Clin Cancer Res; 2006 Jan; 12(2):591-9. PubMed ID: 16428505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
    Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
    Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro migratory aberrancies of mesenchymal stem cells derived from multiple myeloma patients only partially modulated by bortezomib.
    Xu X; Yang J; Tang Y; Li J; Zhu Y; Lu H; Fei X
    Int J Clin Exp Pathol; 2014; 7(10):6705-15. PubMed ID: 25400750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
    Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
    Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.
    Zheng Y; Wang Q; Li T; Qian J; Lu Y; Li Y; Bi E; Reu F; Qin Y; Drazba J; Hsi E; Yang J; Cai Z; Yi Q
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27381622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies.
    Daniel SK; Seo YD; Pillarisetty VG
    Semin Cancer Biol; 2020 Oct; 65():176-188. PubMed ID: 31874281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving α4β1 integrin function.
    García-Bernal D; Redondo-Muñoz J; Dios-Esponera A; Chèvre R; Bailón E; Garayoa M; Arellano-Sánchez N; Gutierrez NC; Hidalgo A; García-Pardo A; Teixidó J
    J Pathol; 2013 Jan; 229(1):36-48. PubMed ID: 22711564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin alpha4beta1 involvement in stromal cell-derived factor-1alpha-promoted myeloma cell transendothelial migration and adhesion: role of cAMP and the actin cytoskeleton in adhesion.
    Parmo-Cabañas M; Bartolomé RA; Wright N; Hidalgo A; Drager AM; Teixidó J
    Exp Cell Res; 2004 Apr; 294(2):571-80. PubMed ID: 15023543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting SDF-1 in multiple myeloma tumor microenvironment.
    Bouyssou JM; Ghobrial IM; Roccaro AM
    Cancer Lett; 2016 Sep; 380(1):315-8. PubMed ID: 26655999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells.
    Abdi J; Rastgoo N; Chen Y; Chen GA; Chang H
    BMC Cancer; 2019 Oct; 19(1):975. PubMed ID: 31638931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.